| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.29 | 0.1 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.088 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.072 | 0.1 |